PNC Financial Services Group Inc. raised its stake in shares of Medtronic PLC (NYSE:MDT – Free Report) by 2.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 658,800 shares of the medical technology company’s stock after buying an additional 17,089 shares during the period. PNC Financial Services Group Inc. owned about 0.05% of Medtronic worth $57,085,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Lodestone Wealth Management LLC bought a new position in shares of Medtronic in the fourth quarter worth about $27,000. Anfield Capital Management LLC grew its stake in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares in the last quarter. Monetary Solutions Ltd purchased a new position in shares of Medtronic during the fourth quarter valued at about $27,000. Acumen Wealth Advisors LLC bought a new stake in Medtronic in the 4th quarter worth approximately $29,000. Finally, Imprint Wealth LLC bought a new stake in Medtronic in the third quarter worth $31,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.
Insider Activity at Medtronic
In other news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares in the company, valued at $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.26% of the stock is owned by company insiders.
Analyst Ratings Changes
Get Our Latest Report on Medtronic
Medtronic Trading Up 0.4%
NYSE MDT opened at $82.19 on Friday. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The company has a market capitalization of $105.20 billion, a PE ratio of 22.03, a P/E/G ratio of 2.20 and a beta of 0.56. The company has a fifty day moving average of $80.01 and a 200 day moving average of $87.55.
Medtronic (NYSE:MDT – Get Free Report) last posted its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping the consensus estimate of $1.54 by $0.01. The firm had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.Medtronic’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the company earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Research analysts forecast that Medtronic PLC will post 5.94 earnings per share for the current year.
Medtronic Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were given a dividend of $0.72 per share. This is a boost from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date was Friday, June 26th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.5%. Medtronic’s payout ratio is 77.21%.
About Medtronic
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Further Reading
- Five stocks we like better than Medtronic
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
